Welcome to our dedicated page for Cannabis Bioscience International Holdings news (Ticker: CBIH), a resource for investors and traders seeking the latest updates and insights on Cannabis Bioscience International Holdings stock.
Cannabis Bioscience International Holdings Inc. (CBIH), trading under the OTC Pink symbol CBIH, is a pioneering entity in the cannabis-based pharmaceutical and biotechnology sectors. Headquartered in Houston, Texas, CBIH specializes in the development of innovative cannabinoid-based therapies aimed at addressing critical and underserved medical conditions. The company’s core mission is to harness the therapeutic potential of cannabinoids through rigorous scientific research, robust intellectual property (IP) strategies, and strategic industry partnerships.
Core Business and Research Focus
At the heart of CBIH’s operations lies its commitment to advancing medical research and clinical applications of cannabinoids. The company has filed an extensive portfolio of utility non-provisional patents covering therapeutic innovations for conditions such as breast and pancreatic cancers, herpes zoster, menopause, knee osteoarthritis, and Alzheimer’s disease. These patents underscore CBIH’s dedication to addressing pressing healthcare challenges with targeted, science-backed solutions. The company’s research and development (R&D) efforts are bolstered by a multidisciplinary team of scientists, medical professionals, and industry experts, ensuring the highest standards of innovation and efficacy.
Intellectual Property and Competitive Edge
CBIH’s robust IP strategy is a cornerstone of its business model. By securing comprehensive patent protections, the company not only safeguards its innovations but also positions itself as a valuable partner for pharmaceutical and biotech firms. The appointment of seasoned professionals, such as Mr. Mauricio Ávila—a patent attorney with extensive experience in pharmaceutical and biotechnology sectors—has significantly enhanced CBIH’s IP capabilities. This strategic focus on IP development provides CBIH with a sustainable competitive advantage, enabling it to monetize its innovations through licensing agreements, strategic alliances, and direct market entry.
Product Development and Distribution
In addition to its R&D and IP initiatives, CBIH is actively engaged in the development and commercialization of nutraceuticals and dietary supplements. These products are designed to leverage the health benefits of cannabinoids while adhering to stringent regulatory standards. The company has established partnerships with leading distributors to ensure efficient manufacturing, marketing, and distribution, thereby expanding its market reach and revenue potential. This multi-channel approach allows CBIH to cater to both consumer and institutional markets, including retail chains and healthcare providers.
Strategic Initiatives and Market Position
CBIH is strategically positioned within the rapidly evolving cannabis and pharmaceutical industries. Its proactive participation in DEA hearings and advocacy for cannabis reclassification highlight its commitment to shaping regulatory frameworks that enable scientific advancement and market growth. The company’s focus on underserved medical conditions, combined with its rigorous clinical trial methodologies, sets it apart from competitors and aligns it with emerging industry trends. Furthermore, CBIH’s emphasis on mergers and acquisitions (M&A) reflects its ambition to scale operations and diversify revenue streams.
Future Outlook
As a forward-thinking company, CBIH aims to capitalize on the growing acceptance and declassification of cannabis to expand its research capabilities and market presence. By integrating cutting-edge technologies, such as artificial intelligence and advanced biotechnological techniques, the company is poised to redefine the landscape of cannabinoid-based therapies. With a strong foundation in IP, a dedicated R&D team, and strategic partnerships, CBIH is well-positioned to drive innovation, improve patient outcomes, and contribute to global health initiatives.
In summary, Cannabis Bioscience International Holdings Inc. represents a unique convergence of science, innovation, and market strategy. Its comprehensive approach to cannabinoid research, intellectual property development, and product commercialization underscores its potential as a transformative player in the healthcare and biotechnology sectors.
CBIH has announced that Brian Cuban, Esq., a notable attorney, best-selling author, and mental health advocate, has joined their Reclassification Team. Cuban will represent CBIH at the DEA hearings on marijuana rescheduling. He brings a unique blend of personal recovery experience and professional advocacy. Cuban, a graduate of Penn State University and The University of Pittsburgh School of Law, has been a vocal champion for individuals facing addiction and mental health challenges. His notable works include 'The Addicted Lawyer' and 'Body Brokers.'
Rosangel Andrades, CBIH R&D Director, praised Cuban's addition, emphasizing the company's commitment to reclassification efforts. Cuban's extensive legal background, with over two decades of experience, makes him a valuable asset in constructing evidence-based arguments for rescheduling marijuana. The reclassification aims to address marijuana's current Schedule I designation under the Controlled Substances Act (CSA), which contradicts modern scientific understanding.
CBIH is dedicated to presenting robust scientific evidence on marijuana's medical benefits, advocating for its reclassification to improve access to treatments for chronic pain, cancer, epilepsy, PTSD, anxiety, and more.
Cannabis Bioscience International Holdings (OTCMKTS: CBIH) has announced a significant partnership with Stephen Gould, a company known for its robust global network and expertise in manufacturing and distribution. This collaboration aims to enhance the delivery of CBIH’s advanced medical product line. Stephen Gould, with over 80 years of experience and operations in more than 40 locations across six countries, brings a wealth of knowledge and a prestigious client portfolio including Walmart, The Children’s Place, GoPro, and Verizon.
According to CBIH’s R&D Director, Rosangel Andrades, this partnership will expedite the market delivery of CBIH's innovative formulations. CBIH will provide its proprietary medical formulations, while Stephen Gould will handle manufacturing and distribution. The first wave of products is expected to launch in the first quarter of 2025.
This partnership is a strategic move for CBIH, aiming to improve market reach and operational efficiency, reaffirming its commitment to delivering quality, science-driven medical solutions.
Cannabis Bioscience International Holdings (CBIH) has filed a petition to include Alexis Bortell as a witness in the upcoming DEA hearing on marijuana rescheduling, scheduled for February 4th. Bortell, diagnosed with intractable epilepsy at age seven, found relief through CBD and THC after conventional treatments failed. Her alternatives were either Felbatol, a drug with serious side effects, or a risky brain surgery.
The company aims to demonstrate through Bortell's testimony that cannabis' Schedule I classification is inappropriate, as it implies no medical use. The current classification has Bortell's career opportunities in medical school and created barriers to accessing her medication, despite keeping her seizure-free for nearly a decade.
Cannabis Bioscience International Holdings (CBIH) CEO Dante Picazo represented the company at DEA Hearing Docket No. 1362 and 24-44 regarding cannabis reclassification. The hearings involve 20 groups debating the potential rescheduling of cannabis from Schedule I to Schedule III. The proposed change could enable advanced medical research, treatment development, and economic growth.
CBIH is seeking expert witnesses, including patients with multiple sclerosis and epilepsy, medical experts, and legal professionals, to participate in the next DEA Hearing. The deadline for participation is December 11, 5:00 PM CT. The company emphasizes that failure to achieve reclassification could delay further discussions for 8-10 years.
Cannabis Bioscience International Holdings (CBIH) participated in a DEA hearing on cannabis reclassification in Arlington, Virginia. CEO Dante Picazo presented a 78-page statement supporting the reclassification of cannabis from its current Schedule I status. The company argues that reclassification would bridge science, policy, and opportunity gaps, potentially leading to economic growth, job creation, and advancement in medical research. A final verdict is expected within two to three months following extensive deliberation. CBIH emphasizes that reclassification would enable responsible medical use and resolve long-standing legal ambiguities.
Cannabis Bioscience International Holdings (OTCMKTS: CBIH) announces the development of the Rejuvenescence Chip, a revolutionary anti-aging device that combines phytocannabinoids and gestrinone. The company holds 13 patents and continues expanding its intellectual property portfolio. The chip offers controlled release of active ingredients for aesthetic, hormonal, and sexual health benefits. Features include improved skin elasticity, reduced fat accumulation, increased muscle mass, hormonal regulation, and enhanced sexual well-being. Dr. Jennifer Salguero explains that treatment requires blood analysis for personalized hormone and endocannabinoid formulation.
Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is strengthening its clinical research team ahead of launching specialized pharmaceutical and nutraceutical cannabinoid products. The company has filed 13 medical patents with the USPTO and expanded its R&D division with notable additions including Dr. Stephanie Hartmann, Dr. Yesiree Baptista, and experts in microbiology, immunology, and pharmacy. CBIH is focusing on developing mRNA vaccines for cancer and other diseases, utilizing molecular biology, nuclear medicine, and advanced technologies. The company aims to capitalize on potential cannabis reclassification from Schedule I to Schedule III and position itself as an attractive partner for larger pharmaceutical firms.
Cannabis Bioscience International Holdings (CBIH) has been selected to participate in the DEA hearings on marijuana rescheduling. CEO Dante Picazo will present clinical trial data demonstrating cannabis's therapeutic benefits. The company will provide evidence on safety and efficacy of cannabis compounds while highlighting economic opportunities from rescheduling.
According to Grand View Research, the U.S. cannabis market was valued at $33.6 billion in 2023, with projected growth of 12.1% annually from 2024 to 2030. CBIH, with ten patent submissions, focuses on developing treatments for conditions including cancer, epilepsy, neurodegenerative diseases, and osteoarthritis.
Cannabis Bioscience International Holdings (CBIH) has appointed Charles Tamburello to its board of directors. With nearly three decades of experience in public markets, Tamburello brings extensive M&A expertise and strategic insights to CBIH. As owner-operator of Global Discovery Group, he has helped hundreds of public and private companies since 1995. His appointment aims to strengthen CBIH's M&A strategy, enhance capital acquisition capabilities, and drive sustainable growth. The company expects his industry connections and expertise to facilitate identifying acquisition targets and maximizing deal success.
Cannabis Bioscience International Holdings (CBIH) has significantly expanded its patent portfolio by filing six utility non-provisional applications for cannabinoid-based therapies. The patents cover treatments for pancreatic cancer, breast cancer, herpes zoster, menopause, knee osteoarthritis, and COVID-19/Influenza. Under the guidance of newly appointed patent attorney Mauricio Ávila, CBIH filed five patents in just five weeks and aims to file more than 15 patents by year-end. The company has also developed a Patent Application Filing Guide for the U.S. market, strengthening its position for potential strategic alliances with major pharmaceutical companies.
FAQ
What is the current stock price of Cannabis Bioscience International Holdings (CBIH)?
What is the market cap of Cannabis Bioscience International Holdings (CBIH)?
What does Cannabis Bioscience International Holdings Inc. (CBIH) specialize in?
How does CBIH generate revenue?
What sets CBIH apart from its competitors?
What types of products does CBIH develop?
What is CBIH’s approach to intellectual property?
How does CBIH contribute to the cannabis industry’s regulatory landscape?
What are CBIH’s key areas of research?
Who are CBIH’s target customers?
What is CBIH’s long-term vision?
How does CBIH ensure the quality of its products?
